A review of phase 2-3 clinical trial designs
From MaRDI portal
Publication:1029784
DOI10.1007/S10985-007-9049-XzbMATH Open1169.62392OpenAlexW2105329903WikidataQ36925837 ScholiaQ36925837MaRDI QIDQ1029784FDOQ1029784
Authors: Peter F. Thall 
Publication date: 13 July 2009
Published in: Lifetime Data Analysis (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/s10985-007-9049-x
Recommendations
- Seamlessly expanding a randomized phase II trial to phase III
- A comparison of methods for constructing confidence intervals after phase II/III clinical trials
- Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations
- Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress
- A three-stage Bayesian adaptive phase I/II design and simulation studies
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Cites Work
- Title not available (Why is that?)
- Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Optimal Dynamic Treatment Regimes
- Title not available (Why is that?)
- Phase 2 and 3 Combination Designs to Accelerate Drug Development
- A Two-Stage Design for Choosing among Several Experimental Treatments and a Control in Clinical Trials
- Two-stage selection and testing designs for comparative clinical trials
- Designs for Group Sequential Phase II Clinical Trials
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- Seamlessly expanding a randomized phase II trial to phase III
- Optimal Designs for a Grouped Sequential Binomial Trial
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
Cited In (9)
- Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials
- Discussion on “A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials” by Elena M. Buzaianu and Pinyuen Chen
- Hybrid design evaluating new biomarkers when there is an existing screening test
- Methodology and application of adaptive and sequential approaches in contemporary clinical trials
- Phase 2 and 3 Combination Designs to Accelerate Drug Development
- Multiple targeted therapies: is there a place for Vach type-3 or type-4 design trials
- Group-sequential response-adaptive designs for multi-armed trials
- A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity
- Interphase Clinical Trials: Phase III/Phase IV
This page was built for publication: A review of phase 2-3 clinical trial designs
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1029784)
